Hemispherx Biopharma (HEB) Receives ANMAT Approval for Commercial Sale of Rintatolimod in Argentine Republic
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (NYSE: HEB) announced that it has received approval of its New Drug Application (NDA) from Administracion Nacional ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
